Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Bristol Myers Squibb Co | 87 |
| 2 | University of California | 80 |
| 3 | Centre National de la Recherche Scientifique | 51 |
| 4 | University of North Carolina System | 46 |
| 5 | Kikkoman Corp | 45 |
| 6 | Cornell University | 36 |
| 7 | Institut National de la Santé et de la Recherche Médicale | 36 |
| 8 | Rutgers, The State University of New Jersey | 33 |
| 9 | Meiji Holdings Co Ltd | 32 |
| 10 | Cartesian Therapeutics Inc | 29 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 2,670 |
| 2 | A61K | Medicinal preparations | 2,596 |
| 3 | C12N | Microorganisms, enzymes | 1,216 |
| 4 | G01N | Investigating / analysing materials | 805 |
| 5 | C07K | Peptides | 781 |
| 6 | C07D | Heterocyclic compounds | 646 |
| 7 | C12Q | Measuring/testing involving enzymes | 432 |
| 8 | C12P | Fermentation, enzyme processes | 270 |
| 9 | Y02A | Climate change adaptation | 236 |
| 10 | C12Y | Enzyme nomenclature (EC numbers) | 231 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Method for preparing oligomycin A and special for bacterial strain thereof | 2009 | 4 | |
| OLIGOMYCIN E | 1988 | Mitsubishi Chemical Group Corp | 4 |
| OLIGOMYCIN SC COMPOUNDS AND ANTICANCER MEDICINE | 1997 | 2 | |
| STRAIN STREPTOMYCES AVERMITILIS PBM 0004 PRODUCING OLIGOMYCINS | 2000 | 1 | |
| Process for the preparation of oligomycin A | 1986 | Bayer AG | 1 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 5 |
| 2017 | 7 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 7 |
| 2021 | 5 |
| 2023 | 2 |
| 2024 | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | В. Н. Даниленко | Vavilov Institute of General Genetics | 7 |
| 2 | Andrey E. Shchekotikhin | Gause Institute of New Antibiotics Russian Academy of Medical Sciences | 6 |
| 3 | Natalia E. Grammatikova | Gause Institute of New Antibiotics Russian Academy of Medical Sciences | 6 |
| 4 | José Marco‐Contelles | Instituto de Química Orgánica General | 6 |
| 5 | Isabel Iriepa | Universidad de Alcalá | 5 |
| 6 | Olga B. Bekker | Vavilov Institute of General Genetics | 5 |
| 7 | Olga A. Omelchuk | Gause Institute of New Antibiotics Russian Academy of Medical Sciences | 4 |
| 8 | Mourad Chioua | Instituto de Química Orgánica General | 4 |
| 9 | Manuela G. López | Universidad Autónoma de Madrid | 4 |
| 10 | María Jesús Oset‐Gasque | Universidad Complutense de Madrid | 4 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| The Use of Oligomycin as an Inhibitor of Oxidative Phosphorylation | 1961 | 241 | Mitochondrial Function and Pathology |
| Mitochondrial dysfunction leads to impairment of insulin sensitivity and adiponectin secretion in adipocytes | 2012 | 175 | Mitochondrial Function and Pathology |
| Down-regulation of Mitochondrial F1F0-ATP Synthase in Human Colon Cancer Cells with Induced 5-Fluorouracil Resistance | 2005 | 169 | Drug Transport and Resistance Mechanisms |
| Apoptolidin, a selective cytotoxic agent, is an inhibitor of F0F1-ATPase | 2001 | 143 | Mitochondrial Function and Pathology |
| Evaluation of intramitochondrial ATP levels identifies G0/G1 switch gene 2 as a positive regulator of oxidative phosphorylation | 2013 | 102 | Mitochondrial Function and Pathology |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition of Oligomycin A?
Which organizations hold the most patents related to Oligomycin A?
How has patent activity for Oligomycin A changed in recent years?
What are the primary research topics associated with Oligomycin A in the scientific literature?
Which patent classification codes are most common for Oligomycin A-related patents?